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UBPY is a ubiquitin-specific protease that can deubiquitinate
monoubiquitinated receptor tyrosine kinases, as well as process
Lys-48- and Lys-63-linked polyubiquitin to lower denomination
forms in vitro. Catalytically inactive UBPY localizes to endosomes,
which accumulate ubiquitinated proteins. We have explored the
sequelae of short interfering RNA-mediated knockdown of UBPY.
Global levels of ubiquitinated protein increase and ubiquitin accu-
mulates on endosomes, although free ubiquitin levels are unchanged.
UBPY-depleted cells have more and larger multivesicular endoso-
mal structures that are frequently associated through extended con-
tact areas, characterized by regularly spaced, electron-dense, bridg-
ing profiles. Degradation of acutely stimulated receptor tyrosine
kinases, epidermal growth factor receptor and Met, is strongly
inhibited in UBPY knockdown cells suggesting that UBPY function
is essential for growth factor receptor down-regulation. In contrast,
stability of the UBPY binding partner STAM is dramatically com-
promised in UBPY knockdown cells. The cellular functions of
UBPY are complex but clearly distinct from those of the Lys-63-
ubiquitin-specific protease, AMSH, with which it shares a binding
site on the SH3 domain of STAM.
Activated receptor tyrosine kinases (RTK)3 generally enter the endo-
somal system through incorporation into clathrin-coated vesicles and
delivery to a tubulo-vesicular compartment known as the early or sort-
ing endosome. From here receptors may recycle to the plasma mem-
brane or be selected for lysosomal sorting by incorporation into small
vesicles that bud away from the limiting membrane into the vacuolar
lumen to generatemultivesicular bodies (MVBs) (1–3). Activated RTKs
such as epidermal growth factor (EGF) receptor (EGFR), platelet-de-
rived growth factor receptor, and Met are multimonoubiquitinated
through the action of an E3 ubiquitin ligase, the proto-oncogene c-Cbl
(4–7). Ubiquitination provides a sorting signal that is proposed to
engage with the MVB sorting machinery through an initial interaction
with the UIM (ubiquitin interacting motif) domain of Hrs (hepatocyte
growth factor receptor tyrosine kinase substrate) (8–10).
Classical studies elucidated polyubiquitin chains linked through an
internal lysine (Lys-48) as a proteasomal degradation signal (11–13).
However, there is an increasing appreciation that alternative polyubiq-
uitin chain structures play crucial roles in cellular physiology (14, 15)
and that ubiquitination is a dynamic post-translational modification,
which may come to rival phosphorylation in its scope and complexity.
The reversibility of ubiquitination can be attributed to the action of
deubiquitinating enzymes (DUBs) of which there are an estimated 79
encoded in the human genome (16, 17).
Two DUBs, associated molecule with the SH3-domain of STAM
(AMSH) and ubiquitin-specific processing protease Y (UBPY) are known
to interact directly with signal transducing adapter molecule (STAM), a
protein that is constitutively associatedwith the endosomal sorting adapter
Hrs (18, 19). In fact, they share a binding site on the SH3 domain of STAM
by virtue of a conserved bindingmotif, PXV/ID/NRXXKP (19). AMSH is a
member of the JAMM/MPN! family of metalloproteases (20, 21), which
we have shown to negatively regulate EGFR sorting to the lysosome as
evidencedbyenhancedreceptordegradation followingacute stimulationof
AMSHknockdown cells (22). UBPY is a cysteine protease of the ubiquitin-
specific processing protease (UBP/USP) family, also known as USP8, and
has been proposed to regulate cellular ubiquitin levels and entry into S
phase (23). The yeast orthologue of UBPY is thought to be Doa4, which
associateswith late componentsof theMVBsortingmachinery (24, 25) and
has been proposed to recycle ubiquitin from committed receptors (26, 27).
In this paper we show that knockdown of UBPY by RNA interference has
multiple cellular effects that include the accumulationofubiquitinatedpro-
teins on endosomes, an increase in both number and size ofmultivesicular
endosomes, and a block in RTK degradation.
EXPERIMENTAL PROCEDURES
Plasmids—HumanUBPY cDNAwas obtained from theKazusaDNA
Research Institute, Japan (cloneKIAA0055) and subcloned into pEGFP-
C1. The C786S mutation was introduced by QuikChange site-directed
mutagenesis (Stratagene) and subcloned into pEGFP-UBPY. A short
interfering (si)RNA-resistant UBPY construct (UBPY*) was generated
by introducing five degenerate point mutations (underlined below)
into UBPY within the region targeted by UBPY-specific siRNA duplex1
(forward primer sequence GCCTATGTACTATATATGAAGTAC-
GTCACGGTGTACAATCTTATC) and subcloning into pEGFPC1-
UBPY. GST-UBPY, HA-STAM, and Flag-ubiquitin constructs were
generous gifts from Giulio Draetta (Milan, Italy), Naomi Kitamura
(Yokohama, pMIW-HA-Hbp), and John O’Bryan (Chicago, IL).
Antibodies and Other Reagents—Mouse monoclonal anti-HA anti-
bodywas fromCovance, and anti-ubiquitin antibodies were fromSigma
(U5379), Covance (P4G7), and Affiniti-Biomol (FK1, FK2). Anti-GFP
was a gift of Francis Barr (Martinsried, Germany). Mouse monoclonal
anti-EGFR R1 and goat polyclonal anti-EGFR 1005 were from Santa
Cruz. Met antibodies were obtained from Cell Signaling. Anti-lyso-
bisphosphatidic acid was a generous gift of Jean Gruenberg (Geneva,
Switzerland). Rabbit polyclonal AMSH, Hrs, and STAM antibodies
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have been previously described (7, 22, 28, 29) Secondary antibodieswere
fromMolecular Probes and Sigma. Protein A- andG-agarose were from
Sigma.
Bacterial Expression and Purification of Recombinant Proteins—GST-
UBPY was expressed in Rosetta (DE3) pLysS cells (Novagen) and batch-
purified with glutathione-Sepharose (Pharmacia) according to manufac-
turers’ instructions.PurifiedproteinwasdialyzedagainstDUB-assaybuffer.
Deubiquitination Assays—Lys-48-linked tetraubiquitin (250 ng) or
Lys-63-linked tetraubiquitin chains (250 ng) (Boston Biochem) were
incubated for 2 h at 37 °C in 20!l of DUB-assay buffer (50mMTris/HCl,
25 mM KCl, 5 mM MgCl2, 1 mM dithiothreitol), pH 8.3, with 1 !M
GST-UBPY. Proteins were resolved on 4–12% NuPAGE gels (Invitro-
gen) according to manufacturer’s instructions. Resolved proteins were
transferred to nitrocellulose (0.2 !m), the membrane was boiled for 30
min in deionized water, blocked in 0.5% fish skin gelatin, 0.1% Tween 20
in phosphate-buffered saline, and probedwith a rabbit antibody to ubiq-
uitin (Sigma) followed by ECL-based detection.
Cell Culture and Transfection—HeLa cells were cultured in 5% CO2
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum and 1% non-essential amino acids. All tissue culture reagents
were purchased from Invitrogen. HeLa cells were transfected with
GeneJuice transfection reagent (Merck Biosciences) and lysed or fixed
24 h post-transfection.
Cell Lysis and Immunoprecipitation—Cells were washed twice in ice-
cold phosphate-buffered saline and lysed inNonidet P-40 lysis buffer (0.5%
Nonidet P-40, 25 mMTris/Cl, pH 7.5, 100 mMNaCl, 50 mMNaF). Lysates
were cleared by centrifugation and incubated with antibodies and Protein
A-orProteinG-agarose for 2hat 4 °C.Alternatively, cellswere lysed in “hot
SDS” lysis buffer (1% SDS, 50mMNaF, 1mM EDTA at 110 °C), and lysates
were heated at 110 °C for 10minwith intermittent vortexing, precleared by
centrifugation at 14,000 rpm for 5 min, and diluted with four volumes of
TX100-dilutionbuffer (1.25%TX100, 25mMTris, pH7.5, 125mMNaCl, 50
mMNaF) prior to immunoprecipitation.
Detection of Ubiquitinated EGFR—siRNA-treated cells were starved
in serum-free medium for 16 h, stimulated with 100 ng/ml EGF for
various times, placed on ice, and lysed in radioimmune precipitation
assay buffer (10 mM Tris/HCl, pH 7.5, 100 mM NaCl, 1% (w/v) Nonidet
P-40, 0.1% (w/v) SDS, 1% (w/v) sodium deoxycholate, and 50 mMNaF),
supplemented with protease inhibitors, phosphatase inhibitors, and 10
mM N-ethylmaleimide. EGFR was immunoprecipitated overnight and
immunoprecipitates were washed in 20 mM Tris/HCl, 150 mM NaCl,
and 0.1% Nonidet P-40 and resuspended in sample buffer. Three-quar-
ters of each sample was analyzed by immunoblotting with anti-ubiq-
uitin, and the remainder was probed in parallel for EGFR, to control for
even loading.
Depletion of Cellular UBPY by siRNA—HeLa cells were treated twice
over 96 h with either control siRNA duplex (nonspecific control VII)
or UBPY-specific siRNA duplex1 (sense UGAAAUACGUGACUGUU-
UAUU, antisense 5"-PUAAACAGUCACGUAUUUCAUU) or UBPY-
specific siRNAduplex 2 (senseGGACAGGACAGUAUAGAUAUU, anti-
sense 5"-PUAUCUAUACUGUCCUGUCCUU, Dharmacon, Lafayette,
CO) andAMSH-specific siRNAduplex (senseUUACAAAUCUGCUGU-
CAUUUU, antisense 5"-PAAUGACAGCAGAUUUGUAAUU, Dharma-
con) at 40.8 nM concentration using Oligofectamine in the absence of
serum (Invitrogen). Four hours post-transfection, fetal bovine serum was
added toa final concentrationof 10%.Alternatively,HeLacellswere treated
twice over 96 h with siRNA at a concentration of 47.2 nM using a calcium
phosphateprotocol. Briefly,mediumwas replacedwith10mlofDulbecco’s
modifiedEagle’smedium!10% fetal bovine serum, 500!l of 0.25MCaCl2,
and 0.52 nmol of siRNA were premixed and added gradually with gentle
vortexing to 500 !l of BBS (50 mM BES, pH 6.95, 280 mM NaCl, 1.5 mM
Na2HP04), incubated for 20min and added dropwise to the cells. The cells
were then incubated at 3% CO2 overnight. The efficiency of UBPY knock-
downwas routinely assessedbyWesternblottinganddeterminedmanually
by counting on a fluorescence microscope the percent of cells showing an
accumulation of ubiquitin on endosomes as shown in Fig. 5E. For the
siRNA-rescue experiment, HeLa cells were treated twice over 96 h with
either control siRNA duplex or UBPY-specific siRNA duplex1. Sixty-six
hours before harvesting, the cells were transfected with pEGFPC1 or pEG-
FPC1-siRNAi resistant UBPY (UBPY*). The percent of GFP-labeled cells,
which retained EGFR after 4 h of EGF treatmentwas determinedmanually
by counting on a fluorescence microscope.
Immunofluorescence—Cells were processed 24 h post-transfection
for immunofluorescence as previously described (8). Secondary anti-
bodies used were labeled with Alexa-Fluor 594 or 488. Dual-stained
confocal images were taken with a Leica confocal SP2 AOBS (HCX PL
APO CS 63.0# 1.40 oil objective).
FIGURE 1. UBPY converts both Lys-48 and Lys-63-linked ubiquitin chains. GST-
UBPY (1 !M) was incubated with enzymatically produced wild-type Lys-48- or Lys-
63-linked tetraubiquitin chains (250 ng, 0.34 !M) for 2 h at 37 °C. Conversion of
tetraubiquitin to free ubiquitin was monitored by SDS-PAGE followed by immuno-
blotting with anti-ubiquitin.
FIGURE 2. Co-localization of UBPY with endosomal markers. HeLa cells were trans-
fectedwith GFP-UBPY (A–C andG–I) or with catalytically inactive GFP-UBPY(C786S) (D–F
and J–L) and either stained with anti-EEA1 (shown in red, A–F) or first starved and then
stimulated for 10 min with 100 ng/ml EGF before staining with anti-EGFR (shown in red,
G–L). All panels represent confocal sections. Insets show 3-fold magnification of the
boxed area. Scale bar, 20 !m.
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Electron Microscopy—Control and UBPY-depleted HeLa cells were
incubated in media containing 10 mg/ml horseradish peroxidase (Sigma)
for 30 min before fixing with 2% glutaraldehyde, 2% paraformaldehyde in
phosphatebuffer, pH7.4. Followingcross-linkingofhorseradishperoxidase
with 0.075% of 3,3"diaminobenzidine tetra hydrochloride (Sigma), 0.023%
H2O2, cellswerepost-fixedwith2.5%glutaraldehyde, osmicated, staineden
blocwith uranyl acetate and processed for Epon embedding according to
standard procedures. Ultrathin (70 nm) sections were cut and stained
with lead citrate before viewing in a Tecnai Spirit electron microscope.
MVBs were identified morphologically by the presence of internal ves-
icles, and their maximal chord lengths were determined using AnalySIS
(SIS, GmbH). Gross changes in MVB abundance were measured by
countingMVBs in cells with a coincident nuclear profile and normaliz-
ing to the total cell area measured with AnalySIS (scrambled: cellular
profiles counted n$ 22, total area of cells examined$ 3353!m2,MVBs
counted n $ 156; UBPY: cellular profiles counted n $ 23, total area of
cells examined area$ 3382 !m2, MVBs counted n$ 230).
RESULTS
Substrate Specificity of UBPY—We have adapted an in vitro assay for
DUB activity that monitors the processing of polyubiquitin chains to
lower denomination forms (22, 30). In our original analysis, AMSH
showed specificity for Lys-63-linked, whereas UBPY showed specificity
for Lys-48-linked polyubiquitin (22). This observation came with the
caveat that the Lys-63-linked chains available to us at that time were
derived frommutant ubiquitin inwhich all lysines, with the exception of
Lys-63, had been converted to arginines. We have now repeated these
experiments with polyubiquitin chains derived from wild-type ubiq-
uitin and find that in contrast to AMSH, UBPY shows little discrimina-
tion between Lys-48 and Lys-63-linked chains (Fig. 1).
Subcellular Distribution of UBPY—We next analyzed the subcellular
localization of UBPY and a catalytically inactive mutant UBPY (C786S)
(23) in HeLa cells. We analyzed cells expressing low levels of GFP-
tagged UBPY and UBPY (C786S) because our UBPY antibody is not
sensitive enough to pick up the endogenous protein. In untreated cells,
both wild-type and inactive UBPY are localized to the cytosol and
plasma membrane (Fig. 2). UBPY (C786S) shows an additional staining
of punctate structures, identified as early endosomes by co-localization
with anti-EEA1 (Fig. 2, D–F) and with internalized EGFR (J–L). Inter-
estingly, wild-type UBPY appears to be recruited to EGFR-containing
early endosomes upon stimulation (Fig. 2, G–I).
Regulation of Ubiquitin Dynamics—Expression of catalytically inac-
tive, but not wild-type, UBPY causes a build up of ubiquitin on endo-
somes; a phenomenon we have previously observed following expres-
sion of catalytically inactive AMSH (D348A) (Fig. 3A) (22). However, in
contrast to AMSH (D348A), this UBPY (C786S) mutant does not pro-
mote accumulation of a higher molecular mass (!14 kDa) form of
STAM (Fig. 3B), which is recognized by ubiquitin antibodies (22).
Both UBPY and AMSH associate with the SH3 domain of STAM via
the same type of non-canonical PXXPmotif and hencemay compete for
binding (19). Effects due to overexpression of catalytically inactive
mutants could reflect displacement of either endogenous UBPY or
AMSH.We therefore turned to RNA interference to address the role of
FIGURE 3.Catalytically inactiveUBPYpromotes accumulationof ubiquitinatedpro-
teins on endosomes. A, HeLa cells were transfectedwith GFP-UBPY or with catalytically
inactive GFP-UBPY(C786S) and stained with anti-ubiquitin antibodies (shown in red). All
panels represent confocal sections. Scale bars, 20 !m. B, HeLa cells were co-transfected
with GFP-tagged wild-type (wt) UBPY or AMSH or catalytically inactive mutant (mut)
UBPY(C786S) or AMSH(D348A) together with HA-STAM. Cells were lysed and GFP-
taggedproteins immunoprecipitated (IP) and analyzed in parallel with the lysates (right-
hand panels) by immunoblotting (IB) with anti-HA antibodies followed by reprobing
with anti-GFP.
FIGURE 4. Depletion of UBPY by siRNA promotes accumulation of polyubiquiti-
nated proteins. HeLa cells were treated with control siRNA (Scr), UBPY-specific siRNA
oligonucleotides (UO1,UO2), or AMSH-specific siRNA (AO2) or left untreated (None). Cells
were lysed after 96 h, and samples analyzedwith anti-UBPY, anti-AMSH, and anti-tubulin
antibodies (A), or with anti-ubiquitin antibodies that either recognize all species of ubiq-
uitinatedproteins including freeubiquitin (B) or specifically reactwithpolyubiquitinated
proteins (C, FK1). IB, immunoblot.
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UBPY in endosomal ubiquitin dynamics (Fig. 4A). Neither treatment of
cells with transfection reagent alone, control (scrambled) siRNA, nor
specific AMSH siRNA had any effect on the overall levels of ubiquiti-
nated proteins as detected by Western blotting (Fig. 4B). In contrast,
knockdown of UBPY, achieved independently with two distinct siRNA
oligonucleotides, resulted in a clear increase in the level of ubiquitinated
proteins. Many of these proteins are polyubiquitinated, based onWest-
ern blotting with a polyubiquitin specific antibody (FK1 (4)) (Fig. 4C).
Although overall ubiquitination was increased, no depletion in the lev-
els of free ubiquitin was observed in UBPY knockdown cells (Fig. 4B).
Immunofluorescence microscopy on UBPY knockdown cells revealed
an accumulation of ubiquitin on endosomes in 84.7% 4.5% (n$ 5, total
number of cells counted 1474) of the cells treatedwithUBPYOligo1 and
83.2 % 3.2% (n $ 4, total number of cells counted 977) treated with
Oligo2, which was not observed in control cells (0.3% 0%, n$ 3, total
number of cells counted 1006) (Fig. 5, A–F). These could be co-labeled
with EEA1, which exhibits a corresponding redistribution to ubiquitin-
positive perinuclear clusters in addition to more characteristic periph-
eral punctae.
Morphological Changes—Using confocal immunofluorescence micros-
copy, we noticed an increased apposition between EEA1-positive endo-
somes and structures containing LBPA, a late endosomal/lysosomal
marker (Fig. 5, G–L) (2, 31). Examination of UBPY knockdown cells by
transmissionelectronmicroscopyrevealed thatknockdowncells contained
an increased number ofmultivesicular endosomal profiles (45% increase of
MVBs/!m2, p& 0.038), which also showed a significant difference in size
distribution with 30.4% of MVBs in UBPY-depleted cells having a maxi-
mumdiameter of'800 nm as comparedwith 9.4% in control-treated cells
FIGURE5.DepletionofUBPYbysiRNApromotesaccumulationofubiquitinonaber-
rantly enlarged endosomes. HeLa cells were treated with control siRNA (Scrambled,
A–C), UBPY-specific siRNA (D–F and J–L) or mock-treated (G–I). Cells were fixed, perme-
ablized, and co-stained for ubiquitin (shown in red, A–I) and EEA1 (in green) or LBPA (in
green, G–L) and EEA1 (in red). All panels represent confocal sections. Insets show 3-fold
magnification of the boxed area. Scale bars, 20 !m.
FIGURE 6.UBPY knockdown promotes accumulation of aberrant pleomorphicmul-
tivesicular structures. Tightly aggregated MVBs that accumulate in the perinuclear
area are a hallmark of HeLa cells treated with UBPY-specific siRNA oligonucleotides (A).
Aberrant MVBs of large diameter some containing only few internal vesicles (*) can also
be observed in UBPY- (B) but not control siRNA-treated cells (C). Analysis of size distribu-
tions based on maximal chord lengths reveals a pool of enlarged MVBs in UBPY knock-
downcells (D).MVBs are also45%moreabundant inUBPY-depleted cells (p&0.038).n$
nucleus;m$mitochondrion; bars$ 100 nm.
FIGURE 7. UBPY knockdown promotes accumulation of MVBs that are attached to
each other via distinctive tethers. Clusters of endosomes display an unusual regular
tethering arrangement (arrows, A and B) that is not seen in control cells. Bars$ 50 nm.
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(Fig. 6, A and D). Another striking feature is the induction of vacuolar
structures, which appear largely empty save for a few luminal vesicles and
which are not seen in control cells (Fig. 6, compare B with C). Electron
microscopy also provides striking views of large numbers of MVBs
“stitched together” along extended areas of close contact by a regularly
spaced repeating unit of electron-dense material with a characteristic
length of 23.3% 3.1 nm (n$ 33) (Fig. 7).
Regulation of RTK Dynamics—EEA1 containing endosomes in UBPY-
depleted cells were accessible to internalized EGFR (and EGF) but in
distinction to endosomes in control cells, retained the receptor for
extended time periods and protected it from degradation (Fig. 8A). This
delay in EGFR degradation could be directly attributed to the loss of
UBPY, because overexpression of siRNA-resistant GFP-tagged UBPY
(UBPY*), but not GFP alone, was able to rescue this phenotype (Fig. 8B).
Co-expression of GFP-UBPY* during the last 66 h of the siRNA-medi-
ated UBPY knockdown, significantly attenuated the delay in EGFR deg-
radation: only 9.8% of GFP-UBPY*-transfected cells showed endosomal
EGFR retention after 4 h of EGF treatment, compared with 75.4% of
cells transfected with GFP alone. Likewise, only 3.1% of GFP-UBPY*-
expressing cells showed an aberrant accumulation of ubiquitin on endo-
somes as compared with 77% of GFP-expressing cells (not shown). We
further confirmed that EGFR down-regulation was defective in UBPY
knockdown cells, by analyzing the same type of experiment usingWest-
ern blotting of cell lysates (Fig. 9A). Following 60 min of acute EGF
stimulation, we routinely detect a diagnostic EGFRdegradation product
that accompanies loss of full-length receptor (indicated by an arrow).
This fragment is not generated in UBPY knockdown cells, and the life-
time of the receptor is significantly extended. It should however be
noted that although this is a very clear block, a slow decline in EGFR
levels is evident nevertheless. We next monitored the ubiquitination
status of the EGFR upon EGF stimulation and found that deubiquitina-
tion of EGFR is severely impaired in UBPY-depleted cells (Fig. 9B),
suggesting that UBPY activity may be required for removal of ubiquitin
from EGFR prior to incorporation into MVBs.
Wewonderedwhether the requirement of UBPY activity was specific
to the down-regulation of EGFR or whether our observation would
translate to other RTKs. We therefore analyzed the down-regulation of
Met, the receptor for hepatocyte growth factor/Scatter factor in UBPY
knockdown cells. Met receptor degradation requires both ubiquitina-
tion and endocytosis (6, 32), although, in distinction to EGFR, it also
shows sensitivity to proteasome inhibitors through an indirect effect on
its trafficking itinerary (33).Met receptor degradation is highly sensitive
to UBPY knockdown and, as for EGFR, the degradation rate is signifi-
cantly slowed in the absence of UBPY (Fig. 9C).
UBPY Regulates the Stability of the Hrs-STAM Complex—How can
knockdown of a DUB retard RTK trafficking while free ubiquitin levels
remain unaltered? One possibility is that UBPY can somehow regulate
the MVB sorting machinery rather than act on the receptors them-
selves. We analyzed the distribution of Hrs in cells that were either
mock-treated or depleted of UBPY or AMSH. In control, as well as in
AMSH-depleted cells, Hrs is distributed between a major cytosolic and
an endosomal pool, which presents as a mixture of peripheral punctate
structures and a more tubulo-reticular perinuclear staining. This distri-
bution is dramatically changed in UBPY-depleted cells; the cytosolic
pool is largely depleted, and Hrs is recruited to aberrantly large perinu-
clear structures (Fig. 10A), which also label for ubiquitin (Fig. 5, D–F).
FIGURE 8.Depletion of UBPY by siRNA inhibits EGF-dependent EGFR down-regula-
tion. A, HeLa cells were treated either with control siRNA (scrambled) or UBPY-specific
siRNA, starved, and then stimulated with 100 ng/ml EGF for 4 h before staining with
anti-EGFR. Scale bar: 20 !m. B, HeLa cells were treated with UBPY-specific siRNA and
subsequently transfected either with GFP alone or siRNA-resistant UBPY (UBPY*). Cells
were starved and stimulated as in A before staining with anti-EGFR. Cells expressing
GFP-UBPY*butnotGFPalone show reduced levels of undegradedEGFR, suggesting that
the degradation of activated EGFR has been restored by recomplementation of UBPY.
Scale bar: 10 !m. All panels represent confocal sections.
FIGURE 9.UBPY is required for the down-regulation of acutely stimulated receptor
tyrosine kinases. A and C, HeLa cells were treated either with control siRNA or UBPY-
specific siRNA, starved, and stimulated with 100 ng/ml EGF or 250 ng/ml HGF for indi-
cated times. Cells were then lysed, and protein samples were analyzed by immunoblot-
ting (IB) with anti-UBPY and anti-EGFR and anti-Met antibodies. Equal loading was
assessed by reprobingwith anti-tubulin. Note the appearance of a diagnostic EGFR deg-
radation product (arrow in A) at 60 min in control cells that is absent from UBPY knock-
down cells. B, HeLa cells were treated as in A, lysed, and immunoprecipitated with anti-
EGFR or without antibody (-"). As a further control, a mock-immunoprecipitation
without lysate was carried out in parallel (-lys). Immunoprecipitates were analyzed by
immunoblotting with anti-ubiquitin (top) and anti-EGFR (bottom).
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We further analyzed SDS-lysates of these cells by Western blotting
and found that the total levels of Hrs were significantly decreased
(50.2% 6.0%, n$ 3) (Fig. 10B). Even more dramatically, we found that
the Hrs-associated adapter protein STAM was effectively depleted in
UBPY knockdown cells (Fig. 10C, '90% depleted, n $ 3). However,
over-expression of STAM in UBPY knockdown cells cannot rescue the
observed defect in EGFR degradation (not shown). DUBs may stabilize
proteins by opposing their ubiquitin-dependent proteasomal degrada-
tion. To test whether this might be the case for regulation of STAM
levels, we treated UBPY knockdown Flag-Ubiquitin-transfected cells
with the proteasomal inhibitor lactacystin. Following lysis of cells under
denaturing conditions with SDS-containing buffer (hot SDS-lysis),
STAM was immunoprecipitated and probed by Western blotting with
anti-FLAG antibodies. Our data indicate that proteasomal inhibition in
UBPY knockdown cells accumulates ubiquitinated STAM, which runs
as a higher molecular weight smear (Fig. 10D). The presence of this
ubiquitin smear is entirely contingent on the knockdown of UBPY.
Interestingly, the levels of AMSH also appeared consistently lower in
cells depleted of UBPY, (Fig. 4A; Oligo1 51.03% % 9.67, n $ 3; Oligo2
70.93% n $ 2, percent of AMSH levels in control cells). It should be
noted that this concomitant loss of AMSH cannot account for the
observed phenotype because depletion of AMSH enhances rather than
delays EGFR down-regulation (22) and does not cause the dramatic
morphological changes we are reporting here.
DISCUSSION
UBPY is a DUB enzyme that shows no substantial discrimination
betweenLys-48- andLys-63-linked polyubiquitin andmay also act upon
monoubiquitinated substrates, such as the platelet-derived growth fac-
tor receptor and EGFR (Fig. 1 and Ref. 34). At least one of the six other
internal lysines within ubiquitin is required for its activity against Lys-
63-linked polyubiquitin, as no activity is detected when these are
mutated (22). Its depletion leads to a global accumulation of ubiquiti-
nated proteins (Fig. 4 (23)) without depleting free ubiquitin levels.
We were interested in comparing the cellular properties of UBPY
with AMSH. These two DUBs share a common binding site with the
SH3 domain of STAM (19) but belong to different DUB families, USP/
UBP and JAMM/MPN!, respectively. In contrast to AMSH, UBPY
shows no association with endosomes in starved cells but can be
recruited following acute EGF stimulation. A recent paper (34) suggests
that UBPY directly interacts with EGFR, althoughwe observed EGF-de-
pendent translocation to endosomes at earlier time points (e.g. 10 min)
than reported for this interaction (between 60 and 120 min). Catalyti-
cally inactive UBPY is found on endosomes in untreated cells, suggest-
ing that its catalytic cycle may be necessary for dissociation frommem-
branes. Catalytically inactive AMSH also shows more pronounced
endosomal staining, and its overexpression, like that of UBPY, leads to
pronounced accumulation of ubiquitin at endosomes. Both effects
could be because of the displacement of endogenous AMSH or UBPY
from their shared binding site to STAM.
We found that catalytically inactive AMSH but not UBPY promotes
the appearance of a ubiquitinated form of STAM, with which it prefer-
entially associates. For reasons still not fully appreciated, several DUBs
physically interact with E3 ligases. Intriguingly, AMSH has been shown
to interact with the RING-finger protein RNF11, which acts as an
adapter for recruitment of the HECT E3-ligases Smurf1/2 and AIP4/
Itch (35). Although ubiquitination of STAM is not well characterized,
one report has implicated AIP4 in the ubiquitination of its binding part-
ner Hrs (36). It may be that AMSH specifically recruits an E3 ligase to
ubiquitinate STAM, which is exclusively stabilized by the catalytically
inactive form of AMSH.
Knockdowns of AMSH and UBPY reveal stark differences. Only UBPY
knockdown leads to changes in the distribution and size of endosomes as
judged by immunofluorescence microscopy and to the accumulation of
both Hrs and ubiquitin at their surface. This led us to examine the mor-
phology of endosomal compartments in UBPY knockdown cells using
transmission electronmicroscopy. There is clearly no block to luminal ves-
icle formation in these cells, asMVBswere in factmore abundant. Clusters
of MVBs are apparently “stitched” together by a repeating electron dense
structure. We speculate that this could correspond to ubiquitinated pro-
teins recognized in trans by ubiquitin binding motifs on the partner endo-
somes. Thus, one aspect of UBPY function may be to disassemble these
tethering structures.
Our biochemical and light microscopic analyses indicate that knock-
FIGURE 10. siRNA knockdown of UBPY causes a redistribution of Hrs and severe
depletion of STAMprotein levels.HeLa cells treated as in Fig. 4 were fixed and stained
with anti-Hrs (A) or lysed in hot SDS-lysis buffer and probed with antibodies against Hrs
and STAM (B and C). Equal loading was assessed by reprobing with anti-tubulin. D,
HeLa cells were treated with control siRNA or UBPY-specific siRNA, transfected with
FLAG-tagged ubiquitin (Ub), and incubated with lactacystin (Lact.) or Me2SO for 7 h.
Lysates were prepared as in B and C and STAM was immunoprecipitated and probed
with horseradish peroxidase-coupled anti-FLAG followed by reprobing with anti-
STAM. IB, immunoblot.
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down of UBPY inhibits RTK degradation. Intriguingly this contrasts
with the AMSH knockdown phenotype for which the rate of EGFR
degradation is clearly enhanced (22). Mizuno et al. (34) have recently
reported a moderate enhancement of EGFR receptor down-regulation
kinetics in UBPY knockdown cells, which is in direct opposition to the
data presented here. Our experiments have been repeated using inde-
pendent transient transfection of two UBPY-specific siRNA duplexes,
whereas the previous findings by Mizuno et al. (34) were based on
transient expression of a single short hairpin pSILENCER construct. In
addition we have been able to rescue the loss of EGFR-degradation by
overexpressing siRNA-resistant GFP-UBPY.While ourmanuscript was
under revision, an unrelated report by Bowers et al. (37) compared the
effect of UBPY and AMSH depletion on 125I-labeled EGF degradation
and is in agreement with our findings.
UBPY is proposed to be an orthologue of the yeast enzyme Doa4, the
deletion of which leads to impaired receptor sorting (26). Doa4 function
is not thought to be essential for the sorting step, but rather acts to
maintain the necessary cellular levels of free ubiquitin. We observed no
depletion in the levels of ubiquitin followingUBPY knockdown suggest-
ing that this is not the mechanism by which receptor sorting is dis-
rupted. How then can the loss of a DUB lead to an inhibition of receptor
down-regulation? One possibility is that UBPY knockdown leads to the
accumulation of aberrantly ubiquitinated receptors, which can no lon-
ger be degraded. An alternative explanation may lie in the significant
depletion of key proteins implicated inMVB sorting that associate with
UBPY. Hrs levels are reduced by (50%. On its own this is unlikely to
lead to a pronounced defect in RTK sorting as higher levels of Hrs
depletion lead to a much more modest suppression of Met degradation
than we see here (2, 7). However, in UBPY-knockdown cells, this is
accompanied by an almost complete loss of the Hrs-associated protein
and UBPY binding partner, STAM. Our data suggest that UBPY may
regulate STAM stability by reversing its polyubiquitination, which in
the absence of UBPY targets STAM for proteasomal degradation. This
may well contribute to the observed sorting defect because Kanazawa
et al. (38) have previously shown that STAM )/) mouse embryonic
fibroblasts are defective in EGFR degradation, and deletion of the yeast
orthologue Hse1 also leads to defects in receptor sorting (39). However,
it is most likely that the pleomorphic effects we observe at the ultra-
structural level, as well as the global accumulation of polyubiquitinated
proteins in UBPY knockdown cells, testify to the existence of multiple
targets for UBPY activity.
In conclusion, the endosomal functions of the two STAM-interacting
DUBs, UBPY andAMSH, are not redundant, with contrasting effects on
the stability and ubiquitination status of STAM itself to the fore. UBPY
may havemultiple effects on endosomal compartments, whichmanifest
as decreased rates of receptor down-regulation and accentuated tether-
ing structures.
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